期刊文献+

冠状动脉重构的血管内超声研究及基质金属蛋白酶和高敏C反应蛋白检测 被引量:6

Intravascular ultrasound study of coronary remodeling and determination of matrix metalloproteinase and hypersensitive C-reactive protein
原文传递
导出
摘要 目的用血管内超声(IVUS)对比研究不同类型冠心病患者的冠状动脉重构(remodeling)特点,探讨冠状动脉重构与临床表现、基质金属蛋白酶(MMPs)及高敏C反应蛋白(hs CRP)的关系。方法在行冠状动脉介入治疗前,应用IVUS研究38例急性冠状动脉综合征(ACS)和18例稳定性心绞痛(SA)患者,测量“罪犯”血管病变处及其近端、远端参考段的外弹力膜(EEM)面积、管腔面积,计算斑块面积和重构指数(RI),定义RI>1.05为正重构,RI<0.95为负重构。识别出高危斑块,检测外周血基质金属蛋白酶2(MMP2)、基质金属蛋白酶9(MMP9)和hs CRP水平。结果ACS组“罪犯”血管处的斑块面积大于SA组[(11.94±4.90)mm2比(9.17±3.36)mm2,P=0.035]。ACS组RI明显大于SA组(0.972±0.222比0.796±0.130,P=0.003)。两组正、负重构分布比率显著不同正重构在ACS组比SA组更常见(34.2%比5.6%,P=0.047),而负重构在SA组更常见(负重构在ACS组和SA组分别为52.6%与88.9%,P=0.003)。ACS组高危斑块发生率多于SA组(76.3%比50.0%,P=0.040)。ACS组患者血清MMP2高于SA组[(250.65±47.97)μg/L比(214.21±47.20)μg/L,P=0.029],前者的血浆MMP9也高于后者[(84.26±9.78)μg/L比(68.46±22.82)μg/L,P=0.038],前者的血清hs CRP亦高于后者[(3.62±3.37)mg/L比(1.48±1.52) ObjectiveTo investigate remodeling characteristics of coronary lesions in patients with acute coronary syndromes (ACS) versus stable angina pectoris (SA) using intravascular ultrasound (IVUS), and to explore the relationship between arterial remodeling and clinical presentation or matrix metalloproteinase (MMPs) or hyper-sensitive C-reactive protein (hs-CRP). Methods We studied culprit lesions of 38 patients with ACS and 18 patients with SA using IVUS before coronary intervention. The lesion site and a proximal or distal reference site including the external elastic membrane (EEM) area and lumen area were analyzed. Plaque area and remodeling index (RI) were calculated, and directions of arterial remodeling were determined. Positive remodeling was defined as RI>1.05 and negative remodeling as RI<0.95. We analyzed the culprit lesion qualitatively, identified high risk plaque and compared them in each group. The blood level of MMP-2、MMP-9 and hs-CRP in each group were also determined.ResultsThe plaque area at culprit lesions in patients with ACS was significantly larger (11.94±4.90 versus 9.17±3.36mm2;P=0.035), and also the RI in ACS group was significantly greater than that of patients with SA (0.972±0.222 versus 0.796±0.130;P=0.003).The distribution of remodeling in these two groups was different: positive remodeling was more frequent in ACS group than in SA group (34.2% versus 5.6%, P=0.047), whereas negative remodeling was more frequent in SA group (52.6% versus 88.9%, P=0.003). There was higher incidence of high risk plaque in ACS group compared to SA (76.3% versus 50.0%, ~P= 0.040). The level of serum MMP-2 in ACS group was higher than that of SA group (250.65±47.97 μg/L versus 214.21±47.20 μg/L, P=0.029). The same applied for plasma MMP-9 (84.26±9.78 μg/L versus 68.46±22.82 μg/L, P=0.038) and serum hs-CRP (3.62±3.37 mg/L versus 1.48±1.52 mg/L, P=0.041). Conclusions Positive remodeling, larger plaque area and higher incidence of high risk plaque are associated with ACS, whereas negative remodeling is more common in patients with SA. This association between the extent of remodeling and clinical presentation may reflect a greater tendency that plaques with positive remodeling can cause ACS. The change of level of MMP-2, MMP-9 and hs-CRP in ACS patients may be helpful in investigating vulnerable plaques.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2005年第5期428-432,共5页 Chinese Journal of Cardiology
  • 相关文献

参考文献14

  • 1Rioufol G,Finet G,Ginon G,et al.Multiple atherosclerotic plaque in acute coronary syndrome:a three-vessel intravascular ultrasound study. Circulation,2002,106:804-808.
  • 2Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med,1987,316:1371-1375.
  • 3Hermiller JB, Tenaglia AN, Kisslo KB, et al. In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. Am J Cardiol,1993,71:665-668.
  • 4Schoenhagen P,Ziada KM,Kapadia SR,et al.Extent and direction of arterial remodeling in stable and unstable coronary syndromes.Circulation,2000,101:598-603.
  • 5Ikeda U,Shimada K.Matrix metalloproteinases and coronary artery diseases.Clin Cardiol,2003,26:55-59.
  • 6Goran K,Hansson.Immune mechanism in atherosclerosis. Arteroscler Thromb Vasc Boil,2001,21:1876-1890.
  • 7不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量:2696
  • 8高润霖.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志,2001,29(12):710-725. 被引量:4988
  • 9陈灏珠.缺血性心脏病的命名和诊断标准[A].见:叶任高 主编.内科学 第5版[C].北京:人民卫生出版社,2000.311-311.
  • 10Fuchs S,Stabile E,Mintz GS,et al.Intravascular ultrasound findings in patients with acute coronary syndromes with and without troponin elevated I level. Am J Cardiol,2002,89:1111-1113

二级参考文献15

  • 1Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Nail Acad Sci USA, 2000, 97: 7458-7463.
  • 2Lutgens E, Cleutjens KBJM, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Nail Aced Sci. USA, 2000, 97: 7464-7469.
  • 3Kai H,Ikeda H, Yasukawa H, et al. Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. J Am Coll Cardiol , 1998,32:368-372.
  • 4Taku T, Toshio H, Hatsuyo K, et al. Cerivastatin, a HMG-CoA Reductase Inhibitor, Improves Endothelial Function In Elderly Diabetics winthin 3 days. Circulation, 2001,104:376-379.
  • 5Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med, 1999,340: 115-126.
  • 6Goran K Hansson. Immune Mechanism In Atherosclerosis Arteroscler Thromb Vasc Biol . 2001,21:1876-1890.
  • 7Koefig W. Inflammation and coronary heart disease:an overview Cardiol Rev, 2001,9:31-35.
  • 8Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation, 1997,96:396-399.
  • 9Brown DL, Hibbs MS, Kearney M, et al. Identification 92 kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation , 1995, 91: 2125-2131.
  • 10Chalmers J, WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for Management of Hypertension. J Hypertens, 1999,17:151-183.

共引文献7536

同被引文献51

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部